Tricky Terrain: Navigating the Pharma Investment Landscape

2022 got off to an uncertain start for the biopharma industry.

The macro-economic outlook is looking increasingly grim, with inflation and interest rates on the up. We have a continuing bear market, slow M&A activity and a very uncertain geo-political climate, so where will the investment opportunities will come from? If it were easy, it wouldn't be so much fun (or indeed so potentially lucrative).

Evaluate's Paul Verdin and Cem Baydar sat down with guest speaker Özgür Tuncer, Investment Partner at Ascension Life Fund, to address the key challenges facing biopharma investors. If you would like to revisit the data and review some of the key themes discussed, please download our webinar slides and on-demand video using the link below.

Discussion Topics:

           •  Where are the safe havens in uncertain times? 

           •  Has the IPO window slammed shut? 

           •  How much longer will venture funding remain the bright spot?   

           •  How can the investment community effectively prioritise early stage investments? 

     

    Paul Verdin

     

       Paul Verdin 
       Head of Services 
       Evaluate Vantage

     

    Cem Baydar

     

       Cem Baydar, Ph.D 
       Chief Consulting Officer 
       Evaluate

     

    Özgür Tuncer

     

       Özgür Tuncer 
       Investment Partner 
       Ascension Life Fund

    Corporate news
    Multimedia

    Share This Article

     
    Tricky Terrain: Navigating the Pharma Investment Landscape
    Webinar slides

    To revisit the data or review some of the key themes discussed, please download the webinar slides.